287 related articles for article (PubMed ID: 24243973)
1. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
[TBL] [Abstract][Full Text] [Related]
2. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
[TBL] [Abstract][Full Text] [Related]
3. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
[TBL] [Abstract][Full Text] [Related]
4. Regulation of actin polymerization by tropomodulin-3 controls megakaryocyte actin organization and platelet biogenesis.
Sui Z; Nowak RB; Sanada C; Halene S; Krause DS; Fowler VM
Blood; 2015 Jul; 126(4):520-30. PubMed ID: 25964668
[TBL] [Abstract][Full Text] [Related]
5. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia.
Spinler KR; Shin JW; Lambert MP; Discher DE
Blood; 2015 Jan; 125(3):525-33. PubMed ID: 25395423
[TBL] [Abstract][Full Text] [Related]
6. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
Pecci A; Malara A; Badalucco S; Bozzi V; Torti M; Balduini CL; Balduini A
Thromb Haemost; 2009 Jul; 102(1):90-6. PubMed ID: 19572073
[TBL] [Abstract][Full Text] [Related]
7. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
[TBL] [Abstract][Full Text] [Related]
8. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.
Pecci A; Canobbio I; Balduini A; Stefanini L; Cisterna B; Marseglia C; Noris P; Savoia A; Balduini CL; Torti M
Hum Mol Genet; 2005 Nov; 14(21):3169-78. PubMed ID: 16162639
[TBL] [Abstract][Full Text] [Related]
9. MYH9 gene mutations associated with bleeding.
Savoia A; De Rocco D; Pecci A
Platelets; 2017 May; 28(3):312-315. PubMed ID: 28368695
[No Abstract] [Full Text] [Related]
10. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.
Pecci A; Ma X; Savoia A; Adelstein RS
Gene; 2018 Jul; 664():152-167. PubMed ID: 29679756
[TBL] [Abstract][Full Text] [Related]
11. Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
Suzuki N; Kunishima S; Ikejiri M; Maruyama S; Sone M; Takagi A; Ikawa M; Okabe M; Kojima T; Saito H; Naoe T; Matsushita T
PLoS One; 2013; 8(8):e71187. PubMed ID: 23976996
[TBL] [Abstract][Full Text] [Related]
12. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
Eckly A; Strassel C; Freund M; Cazenave JP; Lanza F; Gachet C; Léon C
Blood; 2009 Apr; 113(14):3182-9. PubMed ID: 18984861
[TBL] [Abstract][Full Text] [Related]
13. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD.
Léon C; Evert K; Dombrowski F; Pertuy F; Eckly A; Laeuffer P; Gachet C; Greinacher A
Blood; 2012 Apr; 119(14):3333-41. PubMed ID: 22234693
[TBL] [Abstract][Full Text] [Related]
14. Importance of environmental stiffness for megakaryocyte differentiation and proplatelet formation.
Aguilar A; Pertuy F; Eckly A; Strassel C; Collin D; Gachet C; Lanza F; Léon C
Blood; 2016 Oct; 128(16):2022-2032. PubMed ID: 27503502
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion.
Léon C; Eckly A; Hechler B; Aleil B; Freund M; Ravanat C; Jourdain M; Nonne C; Weber J; Tiedt R; Gratacap MP; Severin S; Cazenave JP; Lanza F; Skoda R; Gachet C
Blood; 2007 Nov; 110(9):3183-91. PubMed ID: 17664350
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity.
Sanborn KB; Mace EM; Rak GD; Difeo A; Martignetti JA; Pecci A; Bussel JB; Favier R; Orange JS
Blood; 2011 Nov; 118(22):5862-71. PubMed ID: 22123909
[TBL] [Abstract][Full Text] [Related]
17. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.
Eckly A; Rinckel JY; Laeuffer P; Cazenave JP; Lanza F; Gachet C; Léon C
J Thromb Haemost; 2010 Oct; 8(10):2243-51. PubMed ID: 20695978
[TBL] [Abstract][Full Text] [Related]
18. MYH9-related disease mutations cause abnormal red blood cell morphology through increased myosin-actin binding at the membrane.
Smith AS; Pal K; Nowak RB; Demenko A; Zaninetti C; Da Costa L; Favier R; Pecci A; Fowler VM
Am J Hematol; 2019 Jun; 94(6):667-677. PubMed ID: 30916803
[TBL] [Abstract][Full Text] [Related]
19. Linking the Landscape of
Asensio-Juárez G; Llorente-González C; Vicente-Manzanares M
Cells; 2020 Jun; 9(6):. PubMed ID: 32545517
[TBL] [Abstract][Full Text] [Related]
20. Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA.
Kahr WH; Savoia A; Pluthero FG; Li L; Christensen H; De Rocco D; Traivaree C; Butchart SE; Curtin J; Stollar EJ; Forman-Kay JD; Blanchette VS
Thromb Haemost; 2009 Dec; 102(6):1241-50. PubMed ID: 19967157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]